The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran

Ahangarzadeh Rezaee, 2002, In vitro activity of imipenem and ceftazidime against mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from patients in Iran, Arch Iran Med, 5, 251

Lihua, 2013, Effects of allicin on the formation of Pseudomonas aeruginosa biofinm and the production of quorum-sensing controlled virulence factors, Pol J Microbiol, 62, 243, 10.33073/pjm-2013-032

Wolska, 2009, Genetic features of clinical Pseudomonas aeruginosa strains, Pol J Microbiol, 58, 255

Ahangarzadeh Rezaee, 2002, Higher aminoglycoside resistance in mucoid Pseudomonas aeruginosa than in non-mucoid strains, Arch Iranian Med, 5, 108

Oliveira, 2008, Isolation of Pseudomonas aeruginosa strains from dental office environments and units in Barretos, state of São Paulo, Brazil, and analysis of their susceptibility to antimicrobial drugs, Braz J Microbiol, 39, 579, 10.1590/S1517-83822008000300032

Wolska, 2012, Phenotypic and genotypic diversity of Pseudomonas aeruginosa strains isolated from hospitals in Siedlce (Poland), Braz J Microbiol, 43, 274, 10.1590/S1517-83822012000100032

Perez, 2014, Evaluation of tests to predict metallo-β-lactamase in cystic fibrosis (CF) and non-(CF) Pseudomonas, Braz J Microbiol, 45, 835, 10.1590/S1517-83822014000300011

Strateva, 2009, Pseudomonas aeruginosa – a phenomenon of bacterial resistance, J Med Microbiol, 58, 1133, 10.1099/jmm.0.009142-0

Kugelberg, 2005, Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa, J Antimicrob Chemother, 55, 22, 10.1093/jac/dkh505

Llanes, 2011, Role of the efflux system MexEF-OprN in low level resistance of Pseudomonas aeruginosa to ciprofloxacin, Antimicrob Agents Chemother, 55, 5676, 10.1128/AAC.00101-11

Dalhoff, 2012, Global fluoroquinolone resistance epidemiology and implications for clinical use, Interdisc Perspect Infect Dis, 1, 10.1155/2012/976273

Wydmuch, 2005, gyrA mutations in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa in a Silesian Hospital in Poland, Pol J Microbiol, 54, 201

Akasaka, 1999, Cloning, expression, and enzymatic characterization of Pseudomonas Aeruginosa topoisomerase IV, Antimicrob Agents Chemother, 43, 530, 10.1128/AAC.43.3.530

Agnello, 2012, Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa, PLoS ONE, 7, e42973, 10.1371/journal.pone.0042973

Jalal, 2000, Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients, Antimicrob Agents Chemother, 44, 710, 10.1128/AAC.44.3.710-712.2000

Mouneimné, 1999, Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 43, 62, 10.1128/AAC.43.1.62

Akasaka, 2001, Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance, Antimicrob Agents Chemother, 45, 2263, 10.1128/AAC.45.8.2263-2268.2001

Lee, 2005, Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa, Int J Antimicrob Agents, 25, 290, 10.1016/j.ijantimicag.2004.11.012

Nakano, 1997, Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 41, 2289, 10.1128/AAC.41.10.2289

Salma, 2013, gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon, J Infect Chemother, 19, 77, 10.1007/s10156-012-0455-y

Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms, Clin Microbiol Rev, 22, 582, 10.1128/CMR.00040-09

Japoni, 2009, Pseudomonas aeruginosa: burn infection, treatment and antibacterial resistance, Iran Red Crescent Med J, 2009, 244

Ranjbar, 2011, Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran, Acta Med Iran, 49, 675

Hall, 2007, Nonfermenting and miscellaneous gram-negative bacilli, 564

2010

Gorgani, 2009, Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa, Int J Antimicrob Agents, 34, 414, 10.1016/j.ijantimicag.2009.05.013

Ahangarzadeh Rezaee, 2011, Detection of integrons among multi-drug resistant (MDR) Escherichia coli strains isolated from clinical specimens in northern west of Iran, Braz J Microbiol, 42, 1308, 10.1590/S1517-83822011000400010

Higgins, 2003, Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa, Int J Antimicrob Agents, 21, 409, 10.1016/S0924-8579(03)00009-8

Kureishi, 1994, Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates, Antimicrob Agents Chemother, 38, 1944, 10.1128/AAC.38.9.1944

Takenouchi, 1999, Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones, Antimicrob Agents Chemother, 43, 406, 10.1128/AAC.43.2.406

Sekiguchi, 2007, Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan, J Clin Microbiol, 45, 979, 10.1128/JCM.01772-06

Lambert, 2002, Mechanisms of antibiotic resistance in Pseudomonas aeruginosa, J R Soc Med, 95, 22

Poole, 2000, Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria, Antimicrob Agents Chemother, 44, 2233, 10.1128/AAC.44.9.2233-2241.2000

Van Bambeke, 2003, Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy, J Antimicrob Chemother, 51, 1055, 10.1093/jac/dkg224